Please assess the completion status of the following clinical trial:

Trial Title: Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of bladder carcinoma (\>50% urothelial carcinoma)~* Prior treatment with at least one cycle of platin-based neoadjuvant chemotherapy~* Prior treatment with radical cystectomy revealing pT3NxM0 or pTanyN+M0~* ECOG performance status of 0-1 (Appendix 2).~* No evidence of metastases within 4 weeks of registration~* Adequate organ and marrow function obtained within 14 days of registration~Exclusion Criteria:~* Severe or uncontrolled acute or chronic medical or psychiatric condition~* Prior antiangiogenic therapy~* Prior pelvic radiation for bladder cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous Daily Dosing of Sunitinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).